Search research articles
Contact Us
Filters
Showing results (31-40 of 63) with videos related to
Page
of 7
Sort By:
Experimental Hematology
|
February 26, 2013
NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
Sathisha Upparahalli Venkateshaiah, Sharmin Khan, Wen Ling, et al.
British Journal of Haematology
|
April 25, 2009
Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease
Angela Pennisi, Xin Li, Wen Ling, et al.
Blood
|
October 20, 2009
Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma
Lijuan Chen, Siqing Wang, Yiming Zhou, et al.
Haematologica
|
February 8, 2006
Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model
Shmuel Yaccoby, Michele J Wezeman, Maurizio Zangari, et al.
Cancers
|
September 28, 2023
EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression
Wen Ling, Sarah K Johnson, Syed J Mehdi, et al.
Leukemia Research
|
July 27, 2023
Growth and dormancy control of myeloma cells by mesenchymal stem cells
Syed J Mehdi, Kalyan Ghatak, Wen Ling, et al.
American Journal of Hematology
|
March 5, 2013
Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
Rakesh Bam, Wen Ling, Sharmin Khan, et al.
Haematologica
|
October 19, 2010
A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients
Maurizio Zangari, Shmuel Yaccoby, Lisa Pappas, et al.
British Journal of Haematology
|
September 22, 2005
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma
Maurizio Zangari, Dixie Esseltine, Choon-Kee Lee, et al.
Immunotherapy
|
February 19, 2016
Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Sharmilan Thanendrarajan, Faith E Davies, Gareth J Morgan, et al.
Page
of 7
Search research articles
Search
Showing results (31-40 of 63) with videos related to
Sort By:
Page
of 7
Experimental Hematology
|
February 26, 2013
NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity
Sathisha Upparahalli Venkateshaiah, Sharmin Khan, Wen Ling, et al.
British Journal of Haematology
|
April 25, 2009
Inhibitor of DASH proteases affects expression of adhesion molecules in osteoclasts and reduces myeloma growth and bone disease
Angela Pennisi, Xin Li, Wen Ling, et al.
Blood
|
October 20, 2009
Identification of early growth response protein 1 (EGR-1) as a novel target for JUN-induced apoptosis in multiple myeloma
Lijuan Chen, Siqing Wang, Yiming Zhou, et al.
Haematologica
|
February 8, 2006
Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model
Shmuel Yaccoby, Michele J Wezeman, Maurizio Zangari, et al.
Cancers
|
September 28, 2023
EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression
Wen Ling, Sarah K Johnson, Syed J Mehdi, et al.
Leukemia Research
|
July 27, 2023
Growth and dormancy control of myeloma cells by mesenchymal stem cells
Syed J Mehdi, Kalyan Ghatak, Wen Ling, et al.
American Journal of Hematology
|
March 5, 2013
Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
Rakesh Bam, Wen Ling, Sharmin Khan, et al.
Haematologica
|
October 19, 2010
A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients
Maurizio Zangari, Shmuel Yaccoby, Lisa Pappas, et al.
British Journal of Haematology
|
September 22, 2005
Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma
Maurizio Zangari, Dixie Esseltine, Choon-Kee Lee, et al.
Immunotherapy
|
February 19, 2016
Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Sharmilan Thanendrarajan, Faith E Davies, Gareth J Morgan, et al.
Page
of 7